Semler Scientific Inc. has initiated a Controlled Equity OfferingSM Sales Agreement with several financial institutions, including Barclays Capital Inc. and Cantor Fitzgerald & Co., to raise capital through an at-the-market $(ATM.UK)$ offering program. The company plans to issue and sell up to $500 million of its common stock through this program. As of May 22, 2025, Semler Scientific has successfully issued and sold 3,003,488 shares, generating approximately $114.8 million in net proceeds. This strategic move is part of Semler Scientific's broader efforts to strengthen its financial position.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。